#BIO22: Coming together at a critical time, Endpoints News looks at the key metrics on biopharma in a turbulent time
Back at the beginning of the year during JP Morgan, I came up with my usual set of projections for the year ahead and definitely got one thing wrong. The biotech IPO market, I said in January, would remain weak, creating a major funding issue for biotech.
Here’s me in a discussion with Catalent executive chairman John Chiminski:
What you’ve had for several years is a booming biotech field, lots of money pummeling into the business and pushing it up. So when you remove IPOs as an alternative source of money for a lot of companies, it will make deal-making more (attractive).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.